Moomoo AI 已提取核心訊息
RedHill Biopharma Ltd., a specialty biopharmaceutical company, has announced a registered direct offering to institutional investors, with the sale of 10,000,000 American Depositary Shares (ADSs) at a price of $0.80 per ADS, aiming to raise $8 million in gross proceeds. The offering, expected to close on January 29, 2024, also includes the issuance of unregistered warrants to purchase an equivalent number of ADSs, exercisable at $1.00 per ADS and valid for five years. H.C. Wainwright & Co. is the exclusive placement agent for this offering. The net proceeds are intended for general corporate purposes, including working capital, acquisitions, and research and development. The ADSs are offered under a shelf registration statement on Form F-3, effective since August 9, 2021. The warrants, along with the ADSs underlying them, are issued in a private placement and are not registered under the Securities Act, thus are subject to specific conditions for sale in the United States.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, has announced a registered direct offering to institutional investors, with the sale of 10,000,000 American Depositary Shares (ADSs) at a price of $0.80 per ADS, aiming to raise $8 million in gross proceeds. The offering, expected to close on January 29, 2024, also includes the issuance of unregistered warrants to purchase an equivalent number of ADSs, exercisable at $1.00 per ADS and valid for five years. H.C. Wainwright & Co. is the exclusive placement agent for this offering. The net proceeds are intended for general corporate purposes, including working capital, acquisitions, and research and development. The ADSs are offered under a shelf registration statement on Form F-3, effective since August 9, 2021. The warrants, along with the ADSs underlying them, are issued in a private placement and are not registered under the Securities Act, thus are subject to specific conditions for sale in the United States.
專業生物製藥公司RedHill Biopharma Ltd. 宣佈向機構投資者註冊直接發行，以每股ADS0.80美元的價格出售1,000萬股美國存托股票（ADS），旨在籌集800萬美元的總收益。此次發行預計將於2024年1月29日結束，還包括髮行未註冊的認股權證，以購買同等數量的美國存託憑證，每份ADS的行使價格爲1.00美元，有效期爲五年。H.C. Wainwright & Co. 是本次發行的獨家配售代理。淨收益用於一般公司用途，包括營運資金、收購和研發。美國存託憑證是根據F-3表格的貨架註冊聲明提供的，自2021年8月9日起生效。認股權證及其所依據的美國存託憑證以私募方式發行，未根據《證券法》註冊，因此受美國特定的銷售條件的約束。
專業生物製藥公司RedHill Biopharma Ltd. 宣佈向機構投資者註冊直接發行，以每股ADS0.80美元的價格出售1,000萬股美國存托股票（ADS），旨在籌集800萬美元的總收益。此次發行預計將於2024年1月29日結束，還包括髮行未註冊的認股權證，以購買同等數量的美國存託憑證，每份ADS的行使價格爲1.00美元，有效期爲五年。H.C. Wainwright & Co. 是本次發行的獨家配售代理。淨收益用於一般公司用途，包括營運資金、收購和研發。美國存託憑證是根據F-3表格的貨架註冊聲明提供的，自2021年8月9日起生效。認股權證及其所依據的美國存託憑證以私募方式發行，未根據《證券法》註冊，因此受美國特定的銷售條件的約束。
有用
沒用